Page 158 - Aet News Today

Culturally competent behavioral health provider ReKlame Health is rolling out an in-home program for addiction medicine care in New York City. For patients diagnosed with alcohol use disorder, a registered nurse will come to their home on a monthly basis to administer Naltrexone LAI, a medicine that helps stop cravings for opioids and alcohol.

By investing in Medicaid member engagement, health plans can strengthen their ability to reach members for Medicaid redetermination while taking actions that yield better outcomes and improved financial performance.

Function Oncology goes beyond next-generation sequencing with a CRISPR-based technology that identifies targets for a patient’s cancer regardless of whether or not they are mutated. Now out of stealth, the company will present data validating its approach during the American Association for Cancer Research annual meeting.

Home-based clinical training could enhance skills that are relevant for nurses no matter the care setting. Given the intimate nature of home care, it can be very instructive for understanding the need for a holistic approach to patient care, as well as promoting an empathetic touch.

A joint report by the American Heart Association and Hello Heart found that women die from heart attacks at twice the rate of men and that women are seven times more likely to be misdiagnosed when having a heart attack. In response to the findings, Hello Heart launched a campaign Wednesday to help women understand heart attack symptoms.

Patients with opioid use disorder are more likely to stick with their treatment plan when offered buprenorphine via telemedicine, according to a new study. The study involved 1,378 patients, and their 180-day treatment retention rate was 56.4%.

A federal jury found three former Outcome Health executives guilty of 47 counts of fraud. The convictions come after a 10-week trial that investigated the former leaders’ role in a billion-dollar scheme in which the company lied to its customers about how many physicians' offices their advertisements would appear in.

About 58% of health plans had at least one outcomes-based contract for prescription drugs in 2022, an Avalere Health survey found. More than 35% had more than 10 outcomes-based contracts in 2022.

The FDA has asked for more information about cardiac complications reported last year in a Phase 1 study for the Molecular Templates cancer drug, MT-0169. The partial clinical hold comes as the biotech works through a corporate restructuring as well as second Nasdaq de-listing notice.

A new study from Bessemer Venture Partners analyzed more than 100 venture-backed healthcare companies to determine the best strategies to scale to $100 million in annual recurring revenue. The report laid out a few main lessons health tech companies should know, such as the importance of nurturing relationships with early customers and making sure efficiency metrics are paid close attention.